AN2 Therapeutics, Inc. Accounts Payable
AN2 Therapeutics, Inc. (ANTX) had Accounts Payable of $1.97 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable, Current $1.97M.
- 2026-03-31: Accounts Payable, Current $2.62M.
- 2025-12-31: Accounts Payable, Current $3.02M.
- 2025-09-30: Accounts Payable, Current $2.23M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $1.97M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.62M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $3.02M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $2.23M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.11M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.07M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $3.32M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.71M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.89M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $2.43M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.68M 10-K · filed 2025-03-25 |
| 2023-09-30 | $4.88M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $3.13M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.54M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.12M 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.44M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.61M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.61M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.06M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |